These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38719498)

  • 21. Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.
    Premchand RK; Sharma K; Mittal S; Monteiro R; Libbus I; Ardell JL; Gregory DD; KenKnight BH; Amurthur B; DiCarlo LA; Anand IS
    ESC Heart Fail; 2019 Oct; 6(5):1052-1056. PubMed ID: 31339232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.
    Lewis GD; Voors AA; Cohen-Solal A; Metra M; Whellan DJ; Ezekowitz JA; Böhm M; Teerlink JR; Docherty KF; Lopes RD; Divanji PH; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Felker GM
    JAMA; 2022 Jul; 328(3):259-269. PubMed ID: 35852527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exercise-based cardiac rehabilitation for adults with heart failure.
    Long L; Mordi IR; Bridges C; Sagar VA; Davies EJ; Coats AJ; Dalal H; Rees K; Singh SJ; Taylor RS
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD003331. PubMed ID: 30695817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of trimetazidine on the functional capacity of ischemic heart disease patients not suitable for revascularization: Meta-analysis of randomized controlled trials.
    Ajabnoor A; Mukhtar A
    PLoS One; 2022; 17(2):e0263932. PubMed ID: 35148340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of trimetazidine in nonischemic heart failure: a randomized study.
    Winter JL; Castro PF; Quintana JC; Altamirano R; Enriquez A; Verdejo HE; Jalil JE; Mellado R; Concepción R; Sepúlveda P; Rossel V; Sepúlveda L; Chiong M; García L; Lavandero S
    J Card Fail; 2014 Mar; 20(3):149-54. PubMed ID: 24412523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
    Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A
    Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial.
    Edelmann F; Musial-Bright L; Gelbrich G; Trippel T; Radenovic S; Wachter R; Inkrot S; Loncar G; Tahirovic E; Celic V; Veskovic J; Zdravkovic M; Lainscak M; Apostolović S; Neskovic AN; Pieske B; Düngen HD;
    JACC Heart Fail; 2016 Feb; 4(2):140-149. PubMed ID: 26682793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aldosterone receptor antagonists decrease mortality and cardiovascular hospitalizations in chronic heart failure with reduced left ventricular ejection fraction, but not in chronic heart failure with preserved left ventricular ejection fraction: a meta-analysis of randomized controlled trials.
    DE Vecchis R; Ariano C
    Minerva Cardioangiol; 2017 Aug; 65(4):427-442. PubMed ID: 27958695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of trimetazidine on heart rate variability in patients with heart failure.
    Gunes Y; Guntekin U; Tuncer M; Sahin M
    Arq Bras Cardiol; 2009 Aug; 93(2):154-8. PubMed ID: 19838493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
    Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
    Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischaemic cardiomyopathy.
    Sisakian H; Torgomyan A; Barkhudaryan A
    Acta Cardiol; 2007 Oct; 62(5):493-9. PubMed ID: 17982971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis.
    Zhang L; Lu Y; Jiang H; Zhang L; Sun A; Zou Y; Ge J
    J Am Coll Cardiol; 2012 Mar; 59(10):913-22. PubMed ID: 22381427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do adrenergic alpha-antagonists increase the risk of poor cardiovascular outcomes? A systematic review and meta-analysis.
    Sousa JP; Mendonça D; Teixeira R; Gonçalves L
    ESC Heart Fail; 2022 Oct; 9(5):2823-2839. PubMed ID: 35894772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal denervation in management of heart failure with reduced ejection fraction: A systematic review and meta-analysis.
    Li M; Ma W; Fan F; Yi T; Qiu L; Wang Z; Weng H; Zhang Y; Li J; Huo Y
    J Cardiol; 2023 Jun; 81(6):513-521. PubMed ID: 36758670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trimetazidine shortens QTc interval in patients with ischemic heart failure.
    Zemljic G; Bunc M; Vrtovec B
    J Cardiovasc Pharmacol Ther; 2010 Mar; 15(1):31-6. PubMed ID: 19966175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease.
    Fu EL; Uijl A; Dekker FW; Lund LH; Savarese G; Carrero JJ
    Circ Heart Fail; 2020 Nov; 13(11):e007180. PubMed ID: 33070637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
    Zheng SL; Chan FT; Nabeebaccus AA; Shah AM; McDonagh T; Okonko DO; Ayis S
    Heart; 2018 Mar; 104(5):407-415. PubMed ID: 28780577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.
    Lupón J; Díez-López C; de Antonio M; Domingo M; Zamora E; Moliner P; González B; Santesmases J; Troya MI; Bayés-Genís A
    Eur J Heart Fail; 2017 Dec; 19(12):1615-1623. PubMed ID: 28387002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.
    Docherty KF; Jhund PS; Claggett B; Ferreira JP; Bengtsson O; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; McMurray JJV;
    JAMA Cardiol; 2021 Nov; 6(11):1298-1305. PubMed ID: 34319398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.